Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial
Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial
复制标题
DOI：
10.1002/ejhf.826
复制
发表时间：
2017-11-01
影响因子：
18.2
通讯作者：
Hajjar, Roger J.
中科院分区：
文献类型：
--
作者：
Hulot, Jean-Sebastien;Salem, Joe-Elie;Hajjar, Roger J.
在心力衰竭患者的实验和初步研究中，通过基因转移恢复肌浆网/内质网Ca 2 + ATP酶（SERCA 2a）活性可改善心功能。AGENT-HF（NCT 01966887）试验使用多模态非侵入性心脏成像研究腺相关病毒（AAV 1）/SERCA 2a对心室重构的影响。方法和结果AGENT-HF是在NYHA III-IV级缺血性或非缺血性心力衰竭和左心室射血分数的成人患者中进行的单中心、随机、双盲、安慰剂对照试验
Aims Restoration of sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2a) activity through gene transfer improved cardiac function in experimental and pilot studies in humans with heart failure. The AGENT-HF (NCT01966887) trial investigated the impact of adeno-associated virus (AAV1)/SERCA2a on ventricular remodelling using multimodality non-invasive cardiac imaging.Methods and results AGENT-HF was a single centre, randomized, double-blind, placebo-controlled trial in adult patients with NYHA class III-IV ischaemic or non-ischaemic heart failure and left ventricular ejection fraction